FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295905234> ?p ?o ?g. }

• W4295905234 abstract "Fractional dose is an important strategy to increase access to vaccines. This study evaluated the effectiveness, safety, and immunogenicity of half dose of ChAdOx1 nCoV-19 vaccine. A non-inferiority non-randomized controlled trial compared a half dose of ChAdOx1 nCoV-19 with the full dose, with an interval of 8 to 10 weeks, in individuals aged 18-49 years. The primary endpoints were the incidence rate of new cases/1,000 person-year at 90 days after 14 days of the second dose, confirmed by RT-PCR and new cases registered at SUS National Health Surveillance Database (e-SUS VS). The anti-SARS-CoV-2 spike (S) protein receptor binding domain (RBD) by chemiluminescence and the neutralizing antibodies by plaque reduction neutralization test (PRNT) were titrated. The soluble biomarkers were quantified with a multiplex immunoassay. Follow-up was 90 days after 14 days of the second dose. A total of 29,598 individuals were vaccinated. After exclusion, 16,570 individuals who received half a dose and 6,402 who received full doses were analyzed. The incidence of new cases confirmed by RT-PCR of half dose was non-inferior to full dose (23.7 vs. 25.7 cases per 1,000 persons-year [coefficient group -0.09 CI95%(-0.49 to 0.31)], even after adjusting for age and sex. There were no deaths or hospitalization after immunization of either group. Immunogenicity was evaluated in a subsample (N=558) compared to 154 healthcare workers who received a full dose. The seroconversion rate in seronegative individuals at baseline half dose was 99.8%, similar to that of the full dose (100%). Geometric mean concentration (95% CI; BAU/mL) were half dose = 188 (163-217) and full dose = 529 (423-663) (p < 0.001). In seropositive subjects at baseline (pre-immune individuals), the first dose induced very high and similar IgG-S in half dose 1,359 (1,245-1,483) and full dose 1,354 (1,048-1,749) BAU/mL. A half dose induced a high increase in plasma chemokines, pro-inflammatory/regulatory cytokines, and growth factors. The frequency of adverse events was similar. No serious adverse events or deaths were reported. A half dose of ChAdOx1 nCoV-19 is as effective, safe, and immunogenic as the full dose. The immune response in pre-immune (seropositive in the baseline) individuals indicates that the half dose may be a booster dose schedule." @default.
• W4295905234 created "2022-09-16" @default.
• W4295905234 creator A5001106269 @default.
• W4295905234 creator A5017523406 @default.
• W4295905234 creator A5019063068 @default.
• W4295905234 creator A5022976564 @default.
• W4295905234 creator A5028991987 @default.
• W4295905234 creator A5035360019 @default.
• W4295905234 creator A5047418145 @default.
• W4295905234 creator A5051101558 @default.
• W4295905234 creator A5053799940 @default.
• W4295905234 creator A5055017119 @default.
• W4295905234 creator A5056633426 @default.
• W4295905234 creator A5058020827 @default.
• W4295905234 creator A5064381661 @default.
• W4295905234 creator A5068760960 @default.
• W4295905234 creator A5073277997 @default.
• W4295905234 date "2022-08-29" @default.
• W4295905234 modified "2023-10-14" @default.
• W4295905234 title "Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project" @default.
• W4295905234 cites W2092969802 @default.
• W4295905234 cites W2137012774 @default.
• W4295905234 cites W2143040673 @default.
• W4295905234 cites W2905444998 @default.
• W4295905234 cites W3087924281 @default.
• W4295905234 cites W3108666979 @default.
• W4295905234 cites W3111590711 @default.
• W4295905234 cites W3128853581 @default.
• W4295905234 cites W3129524127 @default.
• W4295905234 cites W3158082784 @default.
• W4295905234 cites W3163785571 @default.
• W4295905234 cites W3183828359 @default.
• W4295905234 cites W3198016518 @default.
• W4295905234 cites W3198902696 @default.
• W4295905234 cites W3200646269 @default.
• W4295905234 cites W3204529355 @default.
• W4295905234 cites W3209733696 @default.
• W4295905234 cites W3217661335 @default.
• W4295905234 cites W4200316526 @default.
• W4295905234 cites W4224839121 @default.
• W4295905234 cites W4225711802 @default.
• W4295905234 doi "https://doi.org/10.3389/fimmu.2022.966416" @default.
• W4295905234 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36105814" @default.
• W4295905234 hasPublicationYear "2022" @default.
• W4295905234 type Work @default.
• W4295905234 citedByCount "3" @default.
• W4295905234 countsByYear W42959052342023 @default.
• W4295905234 crossrefType "journal-article" @default.
• W4295905234 hasAuthorship W4295905234A5001106269 @default.
• W4295905234 hasAuthorship W4295905234A5017523406 @default.
• W4295905234 hasAuthorship W4295905234A5019063068 @default.
• W4295905234 hasAuthorship W4295905234A5022976564 @default.
• W4295905234 hasAuthorship W4295905234A5028991987 @default.
• W4295905234 hasAuthorship W4295905234A5035360019 @default.
• W4295905234 hasAuthorship W4295905234A5047418145 @default.
• W4295905234 hasAuthorship W4295905234A5051101558 @default.
• W4295905234 hasAuthorship W4295905234A5053799940 @default.
• W4295905234 hasAuthorship W4295905234A5055017119 @default.
• W4295905234 hasAuthorship W4295905234A5056633426 @default.
• W4295905234 hasAuthorship W4295905234A5058020827 @default.
• W4295905234 hasAuthorship W4295905234A5064381661 @default.
• W4295905234 hasAuthorship W4295905234A5068760960 @default.
• W4295905234 hasAuthorship W4295905234A5073277997 @default.
• W4295905234 hasBestOaLocation W42959052341 @default.
• W4295905234 hasConcept C126322002 @default.
• W4295905234 hasConcept C159654299 @default.
• W4295905234 hasConcept C168563851 @default.
• W4295905234 hasConcept C203014093 @default.
• W4295905234 hasConcept C2777451964 @default.
• W4295905234 hasConcept C2780868878 @default.
• W4295905234 hasConcept C44249647 @default.
• W4295905234 hasConcept C71924100 @default.
• W4295905234 hasConceptScore W4295905234C126322002 @default.
• W4295905234 hasConceptScore W4295905234C159654299 @default.
• W4295905234 hasConceptScore W4295905234C168563851 @default.
• W4295905234 hasConceptScore W4295905234C203014093 @default.
• W4295905234 hasConceptScore W4295905234C2777451964 @default.
• W4295905234 hasConceptScore W4295905234C2780868878 @default.
• W4295905234 hasConceptScore W4295905234C44249647 @default.
• W4295905234 hasConceptScore W4295905234C71924100 @default.
• W4295905234 hasLocation W42959052341 @default.
• W4295905234 hasLocation W42959052342 @default.
• W4295905234 hasLocation W42959052343 @default.
• W4295905234 hasLocation W42959052344 @default.
• W4295905234 hasOpenAccess W4295905234 @default.
• W4295905234 hasPrimaryLocation W42959052341 @default.
• W4295905234 hasRelatedWork W1647607420 @default.
• W4295905234 hasRelatedWork W1988605508 @default.
• W4295905234 hasRelatedWork W2037139599 @default.
• W4295905234 hasRelatedWork W2052413804 @default.
• W4295905234 hasRelatedWork W2356105321 @default.
• W4295905234 hasRelatedWork W2363499710 @default.
• W4295905234 hasRelatedWork W2371208792 @default.
• W4295905234 hasRelatedWork W2413643813 @default.
• W4295905234 hasRelatedWork W3030518840 @default.
• W4295905234 hasRelatedWork W3092607529 @default.
• W4295905234 hasVolume "13" @default.
• W4295905234 isParatext "false" @default.
• W4295905234 isRetracted "false" @default.
• W4295905234 workType "article" @default.